Skip to main content Skip to search Skip to main navigation
News: EMA

EMA: Revision of Annex 6 - Manufacture of Medicinal Gases

EMA and PIC/S have published a concept paper announcing a targeted revision of Annex 6 Manufacture of Medicinal Gases of the EU GMP Guide. The last update dates from 2010. The revision aims to reflect current manufacturing practice, technological progress and lessons learned from the COVID-19 pandemic.

Key elements under discussion

The revision will be focused and limited in scope, addressing in particular:

  • Premises requirements
    Reassessment of the applicability of general GMP requirements to closed, pressurised gas manufacturing systems.
  • Technological developments
    Consideration of modern safety features such as gas-specific couplings, elimination of containers without residual pressure valves and adapted valve/residual gas checks to reduce contamination risks.
  • Cylinders with integrated pressure regulator flowmeters
    Clarification of inspection requirements before and after refilling and definition of control frequencies; inclusion of cryogenic containers.
  • Medicinal liquid oxygen supply to hospitals
    Strengthening and clarification of documentation and quality assurance requirements for the filling of the hospital’s tank evaporation units.
  • Batch certification (in addition to Annex 16)
    Assessment of potential specific provisions for medicinal gases, including QP availability and possible remote certification aspects.
  • Qualification of facilities and containers
    Clarification regarding qualification of production plants, mobile/stationary tanks and reusable containers.

Timeline

  • Public consultation until 11 April 2026
  • Draft guideline: November 2026
  • Finalisation: 2027


Quelle:

EMA: Concept paper on revision of the guidelines on Good Manufacturing Practice for medicinal products - Annex 6 Manufacture of Medicinal Gases

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

News: EMA

EMA Clarifies Batch Numbering for Parallel-Traded Medicines

EMA updated its GMP/GDP Q&A collection by revising the answer to Question 4 concerning Chapter 5 of the EU GMP Guide. It explains which batch numbers should appear on the packaging of parallel-traded medicines.

Read more
Cleaning Validation: When PDE Reports and the Worst-Case Selection do not Align

Cleaning Validation: When PDE Reports and the Worst-Case Selection do not Align

Robust PDE reports form the basis of risk-based cleaning validation. This article highlights common deficiencies identified during GMP inspections and explains how they can be avoided.

Read more
Question of the Week | GMP-Verlag

Why is it Important to use Consistent Microbiological Air Monitoring Methods in Pharmaceutical Cleanrooms?

Here's the answer:
Read more
News: Europe

EDQM: New Working Party on 3D-printed Medicinal Products

The European Pharmacopoeia Commission (EPC) approved the creation of a working party on 3D-printed medicinal products. Its aim is to support the development of appropriate quality standards in the European Pharmacopoeia (Ph. Eur.).
Read more
EMA: 14 New Nitrosamines for Appendix 1

EMA: 14 New Nitrosamines for Appendix 1

Appendix 1 of EMA’s Questions and Answers on nitrosamine impurities has been updated. This appendix contains acceptable intakes (AIs) established for N-nitrosamines.
Read more
WHO: Draft Revision of its Guidelines on Quality Risk Management

WHO: Draft Revision of its Guidelines on Quality Risk Management

WHO published a revised draft of its “WHO guidelines on quality risk management”. Working document QAS/26.994 is open for public comment until 15 November 2026.
Read more
Previous
Next